Inhaled therapy lowers mortality in patients with ARDS
PHOENIX — More patients with acute respiratory distress syndrome receiving inhaled EXO-CD24 therapy vs. placebo were free of respiratory failure at day 7 and survived at 6 months, according to data presented at the CHEST Annual Meeting.
“The results were remarkable,” Shiran Shapira, PhD, cofounder and chief scientific and technology officer of Nano24, said during her presentation.
In a randomized, double-blind, placebo-controlled phase 2b study, Shapira and colleagues assessed 90 patients with ARDS of any etiology and stage to determine the safety of inhaled EXO-CD24 vs. placebo (aerosolized